Research progress of deubiquitinase in oral squamous cell carcinoma

doi:10.19438/j.cjoms.2024.03.015

Abstract

Abstract: Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in head and neck cancers. Due to the unique location of its onset, it can cause dysfunction of the oral cavity and facial damage, resulting in poor prognosis. The 5-year survival rate is still less than 50%. Its occurrence and development are regulated by multiple signaling pathways. Ubiquitination and deubiquitination are one of the key regulatory mechanisms in protein post translational modifications. More and more studies have found that deubiquitinating enzymes play an important role in the regulation of OSCC related signaling pathways. This article summarized the regulatory mechanisms of deubiquitinating enzymes in different signaling pathways of OSCC, providing a basis for the research of deubiquitinating enzymes in OSCC.

Key words: Oral squamous cell carcinoma, Deubiquitinating enzymes, P53-MDM2, Wnt/β-catenin, NF-κB, Hedgehog

CLC Number:

R739.8

SUN Xiao-mei, DUAN Xiao-feng. Research progress of deubiquitinase in oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(3): 294-299.

References

[1] Cao M, Shi E, Wang H, et al.Personalized targeted therapeutic strategies against oral squamous cell carcinoma. an evidence-based review of literature[J]. Int J Nanomedicine, 2022, 17: 4293-4306.
[2] Johnson DE, Burtness B, Leemans CR, et al.Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92-140.
[3] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4] Gupta S, Gupta R, Sinha DN, et al.Relationship between type of smokeless tobacco & risk of cancer: a systematic review[J]. Indian J Med Res, 2018, 148(1): 56-76.
[5] Bagnardi V, Rota M, Botteri E, et al.Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis[J]. Br J Cancer, 2015, 112(3): 580-593.
[6] Miranda-filho A, Bray F. Global patterns and trends in cancers of the lip, tongue and mouth[J]. Oral Oncol, 2020, 102: 104551.
[7] Li H, Zhang Y, Xu M, et al.Current trends of targeted therapy for oral squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2022, 148(9): 2169-2186.
[8] Canning M, Guo G, Yu M, et al.Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy[J]. Front Cell Dev Biol, 2019, 7: 52-80.
[9] Js H, Hysi D.Methods and risk of bias in molecular marker prognosis studies in oral squamous cell carcinoma[J]. Oral Dis, 2018, 24(1-2): 115-119.
[10] Antao AM, Tyagi A, Kim KS, et al.Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics[J]. Cancers (Basel), 2020, 12(6): 1579-1602.
[11] Cruz Walma DA, Chen Z, Bullock AN, et al.Ubiquitin ligases: guardians of mammalian development[J]. Nat Rev Mol Cell Biol, 2022, 23(5): 350-367.
[12] Sewduth RN, Baietti MF, Sablina AA.Cracking the monoubiquitin code of genetic diseases[J]. Int J Mol Sci, 2020, 21(9): 3036.
[13] Baur R, Rape M.Getting close: insight into the structure and function of K11/K48-branched ubiquitin chains[J]. Structure, 2020, 28(1): 1-3.
[14] Clague MJ, Urbé S, Komander D.Breaking the chains: deubiquitylating enzyme specificity begets function[J]. Nat Rev Mol Cell Biol, 2019, 20(6): 338-352.
[15] Trulsson F, Akimov V, Robu M, et al.Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates[J]. Nat Commun, 2022, 13(1): 2736.
[16] Poondla N, Chandrasekaran AP, Kim KS, et al.Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?[J]. BMB Rep, 2019, 52(3): 181-189.
[17] Das T, Shin SC, Song EJ, et al.Regulation of deubiquitinating enzymes by post-translational modifications[J]. Int J Mol Sci, 2020, 21(11): 4028.
[18] Park J, Cho J, Song EJ.Ubiquitin-proteasome system (UPS) as a target for anticancer treatment[J]. Arch Pharm Res, 2020, 43(11): 1144-1461.
[19] Jin S, Kudo Y, Horiguchi T.The role of deubiquitinating enzyme in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2022, 24(1): 552.
[20] Hassin O, Oren M.Drugging p53 in cancer: one protein, many targets[J]. Nat Rev Drug Discov, 2023, 22(2): 127-144.
[21] Levine AJ. p53: 800 million years of evolution and 40 years of discovery[J]. Nat Rev Cancer, 2020, 20(8): 471-480.
[22] Zhu H, Gao H, Ji Y, et al.Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials[J]. J Hematol Oncol, 2022, 15(1): 91-114.
[23] Xie L, Jia L, Qu J, et al.Expression and prognostic significance of the P53-related DNA damage repair proteins checkpoint kinase 1 (CHK1) and growth arrest and DNA-damage-inducible 45 alpha (GADD45A) in human oral squamous cell carcinoma[J]. Eur J Oral Sci, 2020, 128(2): 128-135.
[24] Hong A, Zhang X, Jones D, et al.Relationships between p53 mutation, HPV status and outcome in oropharyngeal squamous cell carcinoma[J]. Radiother Oncol, 2016, 118(2): 342-349.
[25] Fernández-majada V, Welz PS, Ermolaeva MA, et al. The tumour suppressor CYLD regulates the p53 DNA damage response[J]. Nat Commun, 2016, 7: 12508.
[26] Müller I, Strozyk E, Schindler S, et al. Cancer cells employ nuclear caspase-8 to overcome the p53-dependent G2/M checkpoint through cleavage of USP28[J]. Mol Cell, 2020, 77(5): 970-984.e7.
[27] Prieto-garcia C, Tomaškovic I, Shah VJ, et al. USP28: oncogene or tumor suppressor? a unifying paradigm for squamous cell carcinoma[J]. Cells, 2021, 10(10): 2652.
[28] Khoronenkova SV, Dianova II, Ternette N, et al.ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage[J]. Mol Cell, 2012, 45(6): 801-813.
[29] Hu M, Gu L, Li M, et al.Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway[J]. PLoS Biol, 2006, 4(2): e27.
[30] Zhang MJ, Chen DS, Li H, et al.Clinical significance of USP7 and EZH2 in predicting prognosis of laryngeal squamous cell carcinoma and their possible functional mechanism[J]. Int J Clin Exp Pathol, 2019, 12(6): 2184-2194.
[31] Macdonald BT, Tamai K, He X.Wnt/beta-catenin signaling: components, mechanisms, and diseases[J]. Dev Cell, 2009, 17(1): 9-26.
[32] Steinhart Z, Angers S. Wnt signaling in development and tissue homeostasis[J]. Development, 2018, 145(11): dev146589.
[33] Kyun ML, Kim SO, Lee HG, et al. Wnt3a stimulation promotes primary ciliogenesis through β-catenin phosphorylation-induced reorganization of centriolar satellites[J]. Cell Rep, 2020, 30(5): 1447-1462.e5.
[34] Wang D, Zhang Q, Li F, et al.β-TrCP-mediated ubiquitination and degradation of Dlg5 regulates hepatocellular carcinoma cell proliferation[J]. Cancer Cell Int, 2019, 19: 298-306.
[35] Xie J, Huang L, Lu Y G, et al.Roles of the Wnt signaling pathway in head and neck squamous cell carcinoma[J]. Front Mol Biosci, 2020, 7: 590912.
[36] Huang Y, Hu K, Zhang S, et al.S6K1 phosphorylation-dependent degradation of Mxi1 by β-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer[J]. Theranostics, 2018, 8(5): 1286-1300.
[37] Kim J, Alavi Naini F, Sun Y, et al.Ubiquitin-specific peptidase 2a (USP2a) deubiquitinates and stabilizes β-catenin[J]. Am J Cancer Res, 2018, 8(9): 1823-1836.
[38] Shi J, Liu Y, Xu X, et al.Deubiquitinase USP47/UBP64E regulates β-catenin ubiquitination and degradation and plays a positive role in Wnt signaling[J]. Mol Cell Biol, 2015, 35(19): 3301-3311.
[39] Shang Z, Zhao J, Zhang Q, et al.USP9X-mediated deubiquitination of B-cell CLL/lymphoma 9 potentiates Wnt signaling and promotes breast carcinogenesis[J]. J Biol Chem, 2019, 294(25): 9844-9857.
[40] Wu C, Luo K, Zhao F, et al.USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization[J]. Cell Death Differ, 2018, 25(10): 1855-1869.
[41] da Silva SD, Cunha IW, Nishimoto IN, et al. Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas[J]. Oral Oncol, 2009, 45(10): e134-e139.
[42] Lu R, Wu G, Chen M, et al.USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells[J]. Mol Ther Oncolytics, 2021, 23: 477-487.
[43] Nanayakkara DM, Nguyen MN, Wood SA.Deubiquitylating enzyme, USP9X, regulates proliferation of cells of head and neck cancer lines[J]. Cell Prolif, 2016, 49(4): 494-502.
[44] Jung H, Kim BG, Han WH, et al.Deubiquitination of dishevelled by Usp14 is required for Wnt signaling[J]. Oncogenesis, 2013, 2(8): e64.
[45] Chen X, Wu J, Chen Y, et al.Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma[J]. Int J Biochem Cell Biol, 2016, 79: 350-359.
[46] Tang JY, Xu YH, Lin LC, et al.LY303511 displays antiproliferation potential against oral cancer cells in vitro and in vivo [J]. Environ Toxicol, 2019, 34(8): 958-967.
[47] Oeckinghaus A, Ghosh S.The NF-kappaB family of transcription factors and its regulation[J]. Cold Spring Harb Perspect Biol, 2009, 1(4): a000034.
[48] Eluard B, Nuan-aliman S, Faumont N, et al. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma[J]. Blood, 2022, 139(3): 384-398.
[49] 王爽, 邱林, 刘涵, 等. NF-κB通路对口腔鳞癌细胞迁移和侵袭影响的初步研究[J]. 实用口腔医学杂志, 2022, 38(5): 672-676.
Wang S, Qiu L, Liu H, et al.Effect of NF-κB pathway on migration and invasion of oral squamous cell[J]. Journal of Practical Stomatology, 2022, 38(5): 672-676.
[50] 邵小钧, 朱乔, 刘有, 等. 咀嚼槟榔与口腔鳞癌的相关临床病理学因素分析[J]. 上海口腔医学, 2021, 30(3): 268-272.
Shao XJ, Zhu Q, Liu Y, et al.Analysis of clinicopathological factors related to chewing areca nut and oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2021, 30(3): 268-272.
[51] Micheau O, Tschopp J.Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes[J]. Cell, 2003, 114(2): 181-190.
[52] Hou X, Wang L, Zhang L, et al.Ubiquitin-specific protease 4 promotes TNF-α-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma[J]. FEBS Lett, 2013, 587(4): 311-316.
[53] Morgan EL, Chen Z, Van Waes C.Regulation of NFκB signalling by ubiquitination: a potential therapeutic target in head and neck squamous cell carcinoma?[J]. Cancers(Basel), 2020, 12(10): 2877.
[54] Ge WL, Xu JF, Hu J.Regulation of oral squamous cell carcinoma proliferation through crosstalk between SMAD7 and CYLD[J]. Cell Physiol Biochem, 2016, 38(3): 1209-1217.
[55] Liu S, De Boeck M, van Dam H, et al. Regulation of the TGF-β pathway by deubiquitinases in cancer[J]. Int J Biochem Cell Biol, 2016, 76: 135-145.
[56] Zhang Y, Beachy PA.Cellular and molecular mechanisms of Hedgehog signalling[J]. Nat Rev Mol Cell Biol, 2023, 24(9): 668-687.
[57] Hebrok M, Kim SK, St jacques B, et al. Regulation of pancreas development by hedgehog signaling[J]. Development, 2000, 127(22): 4905-4913.
[58] Chuang PT, Mcmahon AP.Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein[J]. Nature, 1999, 397(6720): 617-621.
[59] Paluszczak J, Wisniewska D, Kostrzewska-poczekaj M, et al. Prognostic significance of the methylation of Wnt pathway antagonists-CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling-ZIC1, ZIC4, and HHIP in head and neck squamous cell carcinomas[J]. Clin Oral Investig, 2017, 21(5): 1777-1788.
[60] Takabatake K, Shimo T, Murakami J, et al.The role of sonic Hedgehog signaling in the tumor microenvironment of oral squamous cell carcinoma[J]. Int J Mol Sci, 2019, 20(22):5779.
[61] Yue S, Chen Y, Cheng SY.Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway[J]. Oncogene, 2009, 28(4): 492-499.
[62] 周紫章. Usp7/HAUSP通过去泛素化Ci/Gli调控Hh信号通路[D]. 南京: 南京大学, 2015.
Zhou ZZ.Usp7/HAUSP regulates Hh signaling pathway by deubiquitinating Ci/Gli[D]. Nangjing: Nanjing University, 2015.
[63] Xia R, Jia H, Fan J, et al.USP8 promotes smoothened signaling by preventing its ubiquitination and changing its subcellular localization[J]. PLoS Biol, 2012, 10(1): e1001238.
[64] Zhou Z, Yao X, Pang S, et al.The deubiquitinase UCHL5/UCH37 positively regulates Hedgehog signaling by deubiquitinating Smoothened[J]. J Mol Cell Biol, 2018, 10(3): 243-257.
[65] Forastiere AA, Goepfert H, Maor M, et al.Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer[J]. N Engl J Med, 2003, 349(22): 2091-2098.
[66] Pignon J P, Bourhis J, Domenge C, et al.Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer[J]. Lancet, 2000, 355(9208): 949-955.
[67] Cengiz Seval G, Beksac M.The safety of bortezomib for the treatment of multiple myeloma[J]. Expert Opin Drug Saf, 2018, 17(9): 953-962.
[68] Suenaga N, Kuramitsu M, Komure K, et al.Loss of tumor suppressor CYLD expression triggers cisplatin resistance in oral squamous cell carcinoma[J]. Int J Mol Sci, 2019, 20(20): 5194.
[69] Tian Z, D'arcy P, Wang X, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance[J]. Blood, 2014, 123(5): 706-716.
[70] Lee HR, Choi WC, Lee S, et al.Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein[J]. Nat Struct Mol Biol, 2011, 18(12): 1336-1344.
[71] Patni AP, Harishankar MK, Joseph JP, et al.Comprehending the crosstalk between Notch, Wnt and Hedgehog signaling pathways in oral squamous cell carcinoma-clinical implications[J]. Cell Oncol (Dordr), 2021, 44(3): 473-494.
[72] Sun T, Liu Z, Yang Q.The role of ubiquitination and deubiquitination in cancer metabolism[J]. Mol Cancer, 2020, 19(1): 146-164.
[73] Tsuchida S, Nakayama T.Ubiquitination and deubiquitination in oral disease[J]. Int J Mol Sci, 2021, 22(11): 5488.